v3 Template
C

Celyad Oncology

Biotechnology ~300 employees
Founded
--
Employees (Est.)
~300
15 leaders known
Total Funding
$9.8M
Funding Rounds
1
Last Funding
2023-08-24

About Celyad Oncology

Celyad Oncology is a cutting-edge biotechnology company focused on pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cell therapies to address cancer indications and overcome limitations of current treatments.

Products & Services

CAR T-cell Therapies:Development of technology platforms and CAR T-cell candidates to target a broad range of cancer indications and address limitations of existing CAR T-cell therapies.

Specialties

Chimeric Antigen Receptor (CAR) T-cell Therapies Cancer Treatment Technologies

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Private Placement
T: -
FT: Private Placement 		A: 9800000
MR: -
FA: approximately EUR 9,800,000
FAN: 9800000 		D: 2023-08-24
FD: 2023-08-24 		3 investors
Private Placement Latest
2023-08-24
$9.8M
3 investors (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

H

Hilde Windels

Chairwoman of the Board

M

Matt Kane

Chief Executive Officer

M

Michel Lussier

Non-Executive Director

S

Serge Goblet

Non-Executive Director

C

Christopher LiPuma

Non-Executive Director

D

Dominic Piscitelli

Independent Director

View 12 more team members with Pro

Unlock Full Team Directory

Recent News

Celyad Oncology Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Website
celyad.com
Industries
Biotechnology
Company Size
~300 employees (est.)

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro